CD40L、sFLT-1、KL-6与重症肺炎患者疾病转归的相关性研究

Correlation between CD40L, sFlt-1, KL-6 and Disease Outcome in Patients with Severe Pneumonia

摘要

目的 探讨CD40配体（CD40L）、可溶性fms样酪氨酸激酶受体-1（sFLT-1）、涎液化糖链抗原-6（KL-6）与重症肺炎（SP）患者疾病转归的相关性研究。方法 选取2020年1月~2022年12月郑州市第三人民医院收治的98例SP患者为研究对象,根据入院后28 d疾病转归情况将患者分为转归良好组（69例）和转归不良组（29例）。比较2组血清CD40L、sFLT-1、KL-6水平和肺功能指标[用力肺活量（FVC）、第1秒用力呼气量（FEV1）、最高呼气流速（PEF）],分析血清各指标水平与肺功能指标及疾病转归的相关性,分析各指标不同水平患者转归不良的危险度。结果 治疗7 d、14 d后转归不良组血清CD40L、sFLT-1、KL-6水平高于转归良好组,FVC、FEV1、PEF低于转归良好组（P<0.05）;治疗7 d、14 d后血清CD40L、sFLT-1、KL-6水平与疾病转归、FVC、FEV1、PEF均呈负相关（P<0.05）;治疗14d后血清CD40L、sFLT-1、KL-6高水平患者转归不良危险度分别是低水平的3.255、3.911、2.322倍（P<0.05）。结论 血清CD40L、sFLT-1、KL-6水平与SP患者疾病转归密切相关,可作为临床预测转归情况的有效指标。

Abstract

Objective To investigate the correlation between CD40 ligand (CD40L), soluble FMS like tyrosine kinase receptor-1 (sFlt-1), salivary liquefied sugar chain antigen-6 (KL-6) and the prognosis of patients with severe pneumonia (SP). Methods Ninety-eight SP patients admitted to Zhengzhou Third People's Hospital from January 2020 to December 2022 were selected as the study objects. According to the disease outcomes 28 days after admission, the patients were divided into a good outcome group (69 cases) and a poor outcome group (29 cases). Serum levels of CD40L, sFLT-1 and KL-6 were compared between the two groups, and the pulmonary function indicators [forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and peak expiratory flow (PEF)] of the two groups were compared, and the correlation between the levels of serum indicators and pulmonary function indicators and disease outcomes was analyzed, and the risk of adverse outcomes of patients with different levels of indicators was analyzed. Results After 7 and 14 days of treatment, the levels of CD40L, sFLT-1 and KL-6 in the poor group were higher than those in the good group, and the levels of FVC, FEV1 and PEF were lower than those in the good group (P<0.05). Serum CD40L, sFLT-1 and KL-6 levels were negatively correlated with disease outcome, FVC, FEV1 and PEF after 7 and 14 days of treatment (P<0.05). After 14 days of treatment, the risk of adverse outcomes in patients with high levels of serum CD40L, sFLT-1 and KL-6 was 3.255, 3.911 and 2.322 times that of low levels, respectively (P<0.05). Conclusion Serum CD40L, sFLT-1 and KL-6 levels are closely related to the disease outcome of SP patients, and can be used as effective indicators to predict the outcome of SP patients.

关键词

重症肺炎 / 疾病转归 / CD40L / sFLT-1 / KL-6

Key words

severe pneumonia / disease outcome / CD40L / sFLT-1 / KL-6

[1] 郑玉君,王茜,秦克,等. ICU重症肺炎用药后鲍曼不动杆菌定植检出率及对病死率的影响[J]. 疑难病杂志,2020,19(6):603-606.
[2] 吴于青,姜国强,刘绉,等. 抗结核药物超敏反应患者PBMCs中T淋巴细胞亚群及CD69、CD40L的表达意义[J]. 重庆医学,2021,50(5):784-786,790.
[3] 沈方方,阮爱春,徐秋霞,等. 血清中可溶性血管内皮生长因子受体-1与多发性子宫肌瘤的相关性分析[J]. 中国临床药理学杂志,2020,36(13):1801-1803.
[4] 贺成光,朱筛成,陈大业. 转化生长因子-β1、Clara细胞分泌蛋白16、Ⅱ型肺泡细胞表面抗原6与支气管肺发育不良的相关性研究[J]. 中国比较医学杂志,2021,31(3):74-81.
[5] 中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J]. 中国急救医学,2016,36(2):97-107.
[6] Mahmoodpoor A, Shadvar K, Sanaie S, et al.Effect of Vitamin C on mortality of critically ill patients with severe pneumonia in intensive care unit: a preliminary study[J]. BMC Infect Dis, 2021, 21(1): 616.
[7] 褚明慧,赵英弟,黄妍. 支气管哮喘合并肺炎支原体感染患儿血清CD40L与血管细胞黏附分子-1水平的变化及意义[J]. 临床和实验医学杂志,2020,19(17):1814-1817.
[8] 全守东,乐原,杜振元,等. 肺炎支原体感染哮喘患儿血清CD40L和VCAM-1水平及意义[J]. 中华医院感染学杂志,2020,30(22):3474-3478.
[9] Hu XX, Zhang AJ, Pan WW, et al.An IgD-Fc-Ig fusion protein restrains the activation of T and B cells by inhibiting IgD-IgDR-Lck signaling in rheumatoid arthritis[J]. Acta Pharmacol Sin, 2022, 43(2): 387-400.
[10] 王琦. 血管生成、心肌重构和心肌细胞损伤标志物在心力衰竭诊断及预后评估中的临床价值[J]. 中西医结合心脑血管病杂志,2021,19(21):3720-3726.
[11] 符征高,陈钰,梁勇,等. 重症肺炎患者血浆sTREM-1、sFLT-1及SOD水平变化及临床意义[J]. 昆明医科大学学报,2021,42(10):132-138.
[12] 周潮艾,冯小伟,王灵,等. 肺炎患儿血清sFlt-1、PlGF表达水平与病情严重程度的关系[J]. 临床肺科杂志,2022,27(10):1472-1475.
[13] 姜丽丽,尚可. 吡非尼酮治疗类风湿关节炎伴肺间质病变的临床观察及其对肺泡细胞表面抗原KL-6的影响[J]. 广东医学,2021,42(11):1352-1355.
[14] 徐健,李先莉,杨丽华,等. 血清涎液化糖链抗原-6对机械通气输血患者发生急性肺损伤的预测价值[J]. 山东医药,2021,61(22):6-9.
[15] 解婷婷,卢芳,梁峰,等. 匹多莫德联合氨溴特罗对支原体肺炎患儿血清KL-6、GM-CSF、炎症因子水平及免疫功能的干预作用[J]. 检验医学与临床,2022,19(8):1040-1044.